IP Library Granted Patent US 11,324,824
Granted Patent B2
US 11,324,824 · App. 16/306,627 · Granted May 10, 2022

Somatic opsins for single cell resolution optogenetics

Inventors: Or A. Shemesh (Somerville, MA); Changyang Linghu (Cambridge, MA); Edward Boyden (Chestnut Hill, MA)
Assignee: Massachusetts Institute of Technology
A61K41/0057A61K38/17A61N5/06A61N5/062C07K14/405C07K14/4716C07K14/705C07K14/70571C12N5/0619C12N13/00C12N15/86G01N33/5058G01N33/566A61K38/00C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,824
App. No.
16/306,627
Granted
May 10, 2022
Kind
B2
Abstract

The invention, in some aspects, relates to polypeptide molecules and their encoding nucleic acid molecules and use of such molecules to target opsins to the soma of cells in which they are expressed. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.

Claims (11)

1. A corn position comprising a fusion protein comprising a soma-targeting polypeptide fused to an opsin polypeptide, wherein the soma-targeting polypeptide comprises a KA2 polypeptide, wherein the KA2 polypeptide amino acid sequence consists of SEQ ID NO: 1, 3, 10, 12, 14 or an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1, 3, 10, 12, or 14, respectively.

2. The composition of claim 1 , wherein the soma-targeting sequence of the KA2 polypeptide has the amino acid sequence of SEQ ID NO: 3, 10, 12 or 14.

3. The composition of claim 1 , wherein the opsin polypeptide is a channelrhodopsin polypeptide.

4. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

5. The composition of claim 1 , wherein the fusion protein further comprises a detectable label.

6. A cell comprising the composition of claim 1 .

7. A method of modulating electrical activity in a cell, the method comprising:

a) expressing in a host cell a fusion protein comprising a soma-targeting polypeptide and an opsin polypeptide, wherein the soma-targeting polypeptide comprises a KA2 polypeptide, wherein the KA2 polypeptide amino acid sequence consists of SEQ ID NO: 1, 3, 10, 12, 14 or an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1, 3, 10, 12, or 14, respectively, and

b) contacting the expressed opsin polypeptide with a light under suitable conditions to activate the opsin polypeptide and modulate an electrical activity in the host cell.

8. The method of claim 7 , wherein the host cell is a vertebrate cell.

9. The method of claim 7 , wherein the host cell is a mammalian cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: SHEMESH, OR A.; LINGHU, CHANGYANG; BOYDEN, EDWARD
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 048756/0146 →
CONFIRMATORY LICENSE Recorded Dec 20, 2018
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047968/0446 →
Continuity (2)
Provisional Application 62345274 · Jun 3, 2016
Related Publication 20190307882A1 · Oct 10, 2019
Cited By (2)
US 12,234,267 US 12,612,438